JOHNSON CITY, Tenn. and NASHVILLE, Tenn., Jan. 21, 2025 /PRNewswire/ -- Crown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance ...

(RTTNews) - Revance Therapeutics, Inc. (RVNC) disclosed on Monday that it has entered into a merger agreement with Crown Laboratories, Inc., which plans to purchase all outstanding shares of Revance's ...

JOHNSON CITY, Tenn., Feb. 27, 2025 /PRNewswire/ -- Crown Laboratories ("Crown"), a fully integrated global skincare and aesthetics company, today announced the appointment of Adelle Walker as Chief ...

The business combination reinforces Crown's position as a leading, innovative, high-growth aesthetics and skincare company Crown, a privately held, fully integrated global skincare company, is ...

"We are pleased to announce the terms of the amended and restated merger agreement, marking an important step forward towards the combination of our complementary organizations," said Jeff Bedard, ...

StriVectin is being acquired after turning around its business under the guidance of chief executive officer Joan Malloy. Crown Laboratories, a Hildred Capital Management LLC-owned portfolio company, ...

Crown Laboratories, Inc. (“Crown Laboratories”), a leading, fully integrated skin care company and Hildred Capital Partners LLC (“Hildred”) portfolio company, today announced the appointment of Thomas ...

JOHNSON CITY, Tenn. (WJHL) – Johnson City-based company Crown Laboratories held a ceremony Friday morning as company leaders broke ground on a multi-million dollar expansion. Crown Labs previously ...

JOHNSON CITY, Tenn. (WJHL) – Crown Laboratories has made some changes to the way it does business as part of its new “Skin Science for Life.” According to a release from Crown, the past two years have ...

Increased offer price to $3.65 per share, a $0.55 per share increase Improved offer unanimously approved by Revance Board of Directors Crown to extend tender offer until 11:59 p.m., Eastern Time, on ...

Under the terms of the Second Amendment, which has been unanimously approved by the Revance Board of Directors, Revance’s stockholders will receive $3.65 per share of common stock, par value $0.001 ...